Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;11(2):e01083.
doi: 10.1002/prp2.1083.

Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19

Rodolfo Pedro Rothlin  1 , Facundo Germán Pelorosso  2 , Mariano Duarte  3   4 , Liliana Nicolosi  5 , Fernandez Criado Ignacio  6 , María Victoria Salgado  7   8 , Héctor Vetulli  9
Affiliations

Telmisartan and losartan: The marked differences between their chemical and pharmacological properties may explain the difference in therapeutic efficacy in hospitalized patients with COVID-19

Rodolfo Pedro Rothlin et al. Pharmacol Res Perspect. 2023 Apr.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Gurwitz D. Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics. Drug Dev Res. 2020;81(5):537‐540. doi:10.1002/DDR.21656 - DOI - PMC - PubMed
    1. Rothlin RP, Vetulli HM, Duarte M, Pelorosso FG. Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID‐19. Drug Dev Res. 2020;81(7):768‐770. doi:10.1002/DDR.21679 - DOI - PMC - PubMed
    1. Liu D, Wu P, Gu W, et al. Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID‐19 compared with recommended drugs. Cell Discov. 2022;8(1):91. doi:10.1038/S41421-022-00454-7 - DOI - PMC - PubMed
    1. Duarte M, Pelorosso F, Nicolosi LN, et al. Telmisartan for treatment of Covid‐19 patients: an open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:37. doi:10.1016/j.eclinm.2021.100962 - DOI - PMC - PubMed
    1. Puskarich MA, Ingraham NE, Merck LH, et al. Efficacy of losartan in hospitalized patients with COVID‐19–induced lung injury: a randomized clinical trial. JAMA Netw Open. 2022;5(3):e222735. doi:10.1001/JAMANETWORKOPEN.2022.2735 - DOI - PMC - PubMed